The combined company will be headquartered in Dublin, Ireland, where Mallinckrodt’s HQ is based, following the close of the merger agreement. Mallinckrodt and Endo said the location of the ...

Mallinckrodt and Endo, pharmaceutical companies that have each encountered business struggles, announced Thursday a $6.7 billion merger that they contend will result in a combined entity with the ...

Mallinckrodt Pharmaceuticals and Endo Inc. plan to merge and create a $6.7 billion company in a move that will cut costs and broaden access to patients and new treatments. The agreement will give ...

All told, the drugmakers project that the combined company will generate $3.6 billion in 2025 revenue, plus earnings of $1.2 billion. The new entity, which will be based out of Mallinckrodt’s ...

After cash consideration, Mallinckrodt shareholders will own 50.1% of the combined entity on a pro forma basis for an implied pro forma enterprise value of $6.7 billion. See Also: Endo Weighing ...

Mallinckrodt Pharmaceuticals plc and Endo Inc. said Thursday they are combining as part of a stock-and-cash deal with an enterprise value of $6.7 billion that will give both companies a roughly 50 ...

The proposed merger comes nearly a year after Endo emerged from bankruptcy protection. Endo Inc. has entered into an agreement to merge with Mallinckrodt in a cash and stock transaction that ...

Mallinckrodt and Endo said. “We see multiple avenues full of growth for the branded business,” Olafsson said on Thursday’s call. According to Olaffson, until now, both companies have been focused ...

while Mallinckrodt shareholders will own the rest for an enterprise value of $6.7 billion, the companies said on Thursday. The merger transforms two companies, previously at risk of closure due to ...